Recruiting
Whey Protein Ingestion and Glucose Control in Pre- and Post Diabetic Individuals
To examine the effects of twice daily whey protein consumption on blood glucose and insulin in pre-diabetic and diabetic individuals
ClinicalTrials.gov IDNCT06694155
PhaseNA
Enrollment40
SponsorUniversity of Arkansas
Age50 Years
SexALL
Conditions studied
Prediabetes / Type 2 Diabetes
About this study
To examine the effects of twice daily whey protein consumption on blood glucose and insulin in pre-diabetic and diabetic individuals
Interventions
- Dietary Supplement: Whey Protein Isolate Crossover — This crossover intervention includes 1 week of whey protein isolate supplementation and 1 week of placebo supplementation.
- Dietary Supplement: Placebo — 1 week of Non-whey protein Placebo supplement
Primary outcomes
- Whole body protein turnover (7 days)
- Oral Glucose Tolerance Test (7 days)
- Blood glucose (7 days)
Eligibility information
Inclusion Criteria:
1. Males and females ages 50-70 years.
2. Body mass index between 25-45 kg/m2
3. Capable of providing informed consent.
4. COVID-19 negative and/or asymptomatic.
5. Willing to abstain from drinking alcohol or consuming marijuana and CBD products during the 7-day study meal period on two occasions.
6. HbA1c: 5.7-6.4% or 6.5% to 7.5% or fasting glucose ≥100 mg/dL
Exclusion Criteria:
1. Subject who does not/will not eat dairy protein sources.
2. Subjects taking exogenous insulin injections or GLP /GIP injections or other appetite suppressants.
3. Unwilling to keep a detailed 7 day food journal on two occasions
4. Unwilling to wear a CGM for 7 days on two occasions and share the data with the research team.
5. Lactose intolerance.
6. Hemoglobin \<10g/dL at screening.
7. History of chemotherapy or radiation therapy for cancer in the 6 months prior to enrollment.
8. History of gastrointestinal bypass/reduction surgery.
9. Pregnant or lactating individuals.
10. History of a chronic inflammatory disease (e.g. Lupus, Crohn's disease)
11. Currently receiving androgen (e.g., testosterone) or anabolic (e.g., GH, IGF-I) therapy.
12. Currently using corticosteroid medications (cortisone, hydrocortisone, prednisone, etc.).
13. Unwilling to avoid using protein or amino-acid supplements during participation.
14. Unwilling to fast overnight.
15. Any medical condition or medication that the PI or clinical study staff finds contradictory to this study.
Study locations
- University of Arkansas for Medical Sciences, Little Rock, Arkansas 72202 United States
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-30.